Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis
The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28...
Gespeichert in:
| Veröffentlicht in: | Innate immunity (London, England) England), 2017-10, Vol.23 (7), p.606-614 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 614 |
|---|---|
| container_issue | 7 |
| container_start_page | 606 |
| container_title | Innate immunity (London, England) |
| container_volume | 23 |
| creator | Gamez-Nava, Jorge I. Bonilla-Lara, David Ponce-Guarneros, Juan M. Zuñiga-Mora, J. Alejandro Perez-Guerrero, Edsaul E. Murillo-Vazquez, Jessica D. Becerra-Alvarado, Itzel N. Rodriguez-Jimenez, N. Alejandra Saldaña-Cruz, A. Miriam Vazquez-Villegas, M. Luisa Vera-Navarrete, Erika Y. Gonzalez-Ponce, Fabiola Gonzalez-Lopez, Laura |
| description | The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire–Disability Index (HAQ-DI), patient’s perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics. |
| doi_str_mv | 10.1177/1753425917726862 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1936265983</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1753425917726862</sage_id><sourcerecordid>1936265983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-47043328dc6f63e35ac08f9b4e347ce56592c50898b836c92ca5ef45427919d43</originalsourceid><addsrcrecordid>eNp1kUtv1TAQhS0Eog_Ys0JelkXA78cSVS1FKkJC7TpynMm9LkkcbEfq_Tv8Uhzd0gUSq5mxz_mko4PQO0o-Uqr1J6olF0zaujNlFHuBTrenRjClXz7v0p6gs5wfCFGMSP0anTBjtKKCnqLf9yWMoRxwHHCO49qNgEsKux2kMO9wAg9LiQnD45IgZ-hxnPF0gDGGHnsYx9xQfJHvflx9a-gH7DLuQpxc-gkJl4irqQ--4LKH5BZYS_CVmZc4Z9j-Jyj7WBI8ugI4zDjtYZ1c2eAulX0KJeQ36NXgxgxvn-Y5ur--uru8aW6_f_l6-fm28Vzb0ghNBOfM9F4NigOXzhMz2E4AF9qDVNIyL4mxpjNc-Xo4CYOQgmlLbS_4Obo4cpcUf62QSzuFvEV0M8Q1t9RyxSrF8ColR6lPMecEQ7ukUFMfWkrarZn232aq5f0Tfe0m6J8Nf6uoguYoyG4H7UNc01zT_h_4BxkymFM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1936265983</pqid></control><display><type>article</type><title>Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis</title><source>Sage Journals GOLD Open Access 2024</source><creator>Gamez-Nava, Jorge I. ; Bonilla-Lara, David ; Ponce-Guarneros, Juan M. ; Zuñiga-Mora, J. Alejandro ; Perez-Guerrero, Edsaul E. ; Murillo-Vazquez, Jessica D. ; Becerra-Alvarado, Itzel N. ; Rodriguez-Jimenez, N. Alejandra ; Saldaña-Cruz, A. Miriam ; Vazquez-Villegas, M. Luisa ; Vera-Navarrete, Erika Y. ; Gonzalez-Ponce, Fabiola ; Gonzalez-Lopez, Laura</creator><creatorcontrib>Gamez-Nava, Jorge I. ; Bonilla-Lara, David ; Ponce-Guarneros, Juan M. ; Zuñiga-Mora, J. Alejandro ; Perez-Guerrero, Edsaul E. ; Murillo-Vazquez, Jessica D. ; Becerra-Alvarado, Itzel N. ; Rodriguez-Jimenez, N. Alejandra ; Saldaña-Cruz, A. Miriam ; Vazquez-Villegas, M. Luisa ; Vera-Navarrete, Erika Y. ; Gonzalez-Ponce, Fabiola ; Gonzalez-Lopez, Laura</creatorcontrib><description>The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire–Disability Index (HAQ-DI), patient’s perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics.</description><identifier>ISSN: 1753-4259</identifier><identifier>EISSN: 1753-4267</identifier><identifier>DOI: 10.1177/1753425917726862</identifier><identifier>PMID: 28876141</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Biomarkers, Pharmacological - metabolism ; Cohort Studies ; Disease Progression ; Female ; Follow-Up Studies ; Humans ; Male ; Methotrexate - therapeutic use ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Sensitivity and Specificity ; Surveys and Questionnaires ; Triggering Receptor Expressed on Myeloid Cells-1 - metabolism ; Young Adult</subject><ispartof>Innate immunity (London, England), 2017-10, Vol.23 (7), p.606-614</ispartof><rights>The Author(s) 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-47043328dc6f63e35ac08f9b4e347ce56592c50898b836c92ca5ef45427919d43</citedby><cites>FETCH-LOGICAL-c379t-47043328dc6f63e35ac08f9b4e347ce56592c50898b836c92ca5ef45427919d43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1753425917726862$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1753425917726862$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21945,27830,27901,27902,44921,45309</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1753425917726862?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28876141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gamez-Nava, Jorge I.</creatorcontrib><creatorcontrib>Bonilla-Lara, David</creatorcontrib><creatorcontrib>Ponce-Guarneros, Juan M.</creatorcontrib><creatorcontrib>Zuñiga-Mora, J. Alejandro</creatorcontrib><creatorcontrib>Perez-Guerrero, Edsaul E.</creatorcontrib><creatorcontrib>Murillo-Vazquez, Jessica D.</creatorcontrib><creatorcontrib>Becerra-Alvarado, Itzel N.</creatorcontrib><creatorcontrib>Rodriguez-Jimenez, N. Alejandra</creatorcontrib><creatorcontrib>Saldaña-Cruz, A. Miriam</creatorcontrib><creatorcontrib>Vazquez-Villegas, M. Luisa</creatorcontrib><creatorcontrib>Vera-Navarrete, Erika Y.</creatorcontrib><creatorcontrib>Gonzalez-Ponce, Fabiola</creatorcontrib><creatorcontrib>Gonzalez-Lopez, Laura</creatorcontrib><title>Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis</title><title>Innate immunity (London, England)</title><addtitle>Innate Immun</addtitle><description>The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire–Disability Index (HAQ-DI), patient’s perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics.</description><subject>Adult</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biomarkers, Pharmacological - metabolism</subject><subject>Cohort Studies</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Sensitivity and Specificity</subject><subject>Surveys and Questionnaires</subject><subject>Triggering Receptor Expressed on Myeloid Cells-1 - metabolism</subject><subject>Young Adult</subject><issn>1753-4259</issn><issn>1753-4267</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtv1TAQhS0Eog_Ys0JelkXA78cSVS1FKkJC7TpynMm9LkkcbEfq_Tv8Uhzd0gUSq5mxz_mko4PQO0o-Uqr1J6olF0zaujNlFHuBTrenRjClXz7v0p6gs5wfCFGMSP0anTBjtKKCnqLf9yWMoRxwHHCO49qNgEsKux2kMO9wAg9LiQnD45IgZ-hxnPF0gDGGHnsYx9xQfJHvflx9a-gH7DLuQpxc-gkJl4irqQ--4LKH5BZYS_CVmZc4Z9j-Jyj7WBI8ugI4zDjtYZ1c2eAulX0KJeQ36NXgxgxvn-Y5ur--uru8aW6_f_l6-fm28Vzb0ghNBOfM9F4NigOXzhMz2E4AF9qDVNIyL4mxpjNc-Xo4CYOQgmlLbS_4Obo4cpcUf62QSzuFvEV0M8Q1t9RyxSrF8ColR6lPMecEQ7ukUFMfWkrarZn232aq5f0Tfe0m6J8Nf6uoguYoyG4H7UNc01zT_h_4BxkymFM</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>Gamez-Nava, Jorge I.</creator><creator>Bonilla-Lara, David</creator><creator>Ponce-Guarneros, Juan M.</creator><creator>Zuñiga-Mora, J. Alejandro</creator><creator>Perez-Guerrero, Edsaul E.</creator><creator>Murillo-Vazquez, Jessica D.</creator><creator>Becerra-Alvarado, Itzel N.</creator><creator>Rodriguez-Jimenez, N. Alejandra</creator><creator>Saldaña-Cruz, A. Miriam</creator><creator>Vazquez-Villegas, M. Luisa</creator><creator>Vera-Navarrete, Erika Y.</creator><creator>Gonzalez-Ponce, Fabiola</creator><creator>Gonzalez-Lopez, Laura</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201710</creationdate><title>Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis</title><author>Gamez-Nava, Jorge I. ; Bonilla-Lara, David ; Ponce-Guarneros, Juan M. ; Zuñiga-Mora, J. Alejandro ; Perez-Guerrero, Edsaul E. ; Murillo-Vazquez, Jessica D. ; Becerra-Alvarado, Itzel N. ; Rodriguez-Jimenez, N. Alejandra ; Saldaña-Cruz, A. Miriam ; Vazquez-Villegas, M. Luisa ; Vera-Navarrete, Erika Y. ; Gonzalez-Ponce, Fabiola ; Gonzalez-Lopez, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-47043328dc6f63e35ac08f9b4e347ce56592c50898b836c92ca5ef45427919d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biomarkers, Pharmacological - metabolism</topic><topic>Cohort Studies</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Sensitivity and Specificity</topic><topic>Surveys and Questionnaires</topic><topic>Triggering Receptor Expressed on Myeloid Cells-1 - metabolism</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gamez-Nava, Jorge I.</creatorcontrib><creatorcontrib>Bonilla-Lara, David</creatorcontrib><creatorcontrib>Ponce-Guarneros, Juan M.</creatorcontrib><creatorcontrib>Zuñiga-Mora, J. Alejandro</creatorcontrib><creatorcontrib>Perez-Guerrero, Edsaul E.</creatorcontrib><creatorcontrib>Murillo-Vazquez, Jessica D.</creatorcontrib><creatorcontrib>Becerra-Alvarado, Itzel N.</creatorcontrib><creatorcontrib>Rodriguez-Jimenez, N. Alejandra</creatorcontrib><creatorcontrib>Saldaña-Cruz, A. Miriam</creatorcontrib><creatorcontrib>Vazquez-Villegas, M. Luisa</creatorcontrib><creatorcontrib>Vera-Navarrete, Erika Y.</creatorcontrib><creatorcontrib>Gonzalez-Ponce, Fabiola</creatorcontrib><creatorcontrib>Gonzalez-Lopez, Laura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Innate immunity (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Gamez-Nava, Jorge I.</au><au>Bonilla-Lara, David</au><au>Ponce-Guarneros, Juan M.</au><au>Zuñiga-Mora, J. Alejandro</au><au>Perez-Guerrero, Edsaul E.</au><au>Murillo-Vazquez, Jessica D.</au><au>Becerra-Alvarado, Itzel N.</au><au>Rodriguez-Jimenez, N. Alejandra</au><au>Saldaña-Cruz, A. Miriam</au><au>Vazquez-Villegas, M. Luisa</au><au>Vera-Navarrete, Erika Y.</au><au>Gonzalez-Ponce, Fabiola</au><au>Gonzalez-Lopez, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis</atitle><jtitle>Innate immunity (London, England)</jtitle><addtitle>Innate Immun</addtitle><date>2017-10</date><risdate>2017</risdate><volume>23</volume><issue>7</issue><spage>606</spage><epage>614</epage><pages>606-614</pages><issn>1753-4259</issn><eissn>1753-4267</eissn><abstract>The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire–Disability Index (HAQ-DI), patient’s perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>28876141</pmid><doi>10.1177/1753425917726862</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1753-4259 |
| ispartof | Innate immunity (London, England), 2017-10, Vol.23 (7), p.606-614 |
| issn | 1753-4259 1753-4267 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1936265983 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Biomarkers, Pharmacological - metabolism Cohort Studies Disease Progression Female Follow-Up Studies Humans Male Methotrexate - therapeutic use Middle Aged Predictive Value of Tests Prognosis Prospective Studies Sensitivity and Specificity Surveys and Questionnaires Triggering Receptor Expressed on Myeloid Cells-1 - metabolism Young Adult |
| title | Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T17%3A32%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20soluble%20triggering%20receptor%20expressed%20on%20myeloid%20cells-1%20(sTREM-1)%20as%20biomarker%20to%20predict%20therapeutic%20response%20to%20methotrexate%20in%20rheumatoid%20arthritis&rft.jtitle=Innate%20immunity%20(London,%20England)&rft.au=Gamez-Nava,%20Jorge%20I.&rft.date=2017-10&rft.volume=23&rft.issue=7&rft.spage=606&rft.epage=614&rft.pages=606-614&rft.issn=1753-4259&rft.eissn=1753-4267&rft_id=info:doi/10.1177/1753425917726862&rft_dat=%3Cproquest_AFRWT%3E1936265983%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1936265983&rft_id=info:pmid/28876141&rft_sage_id=10.1177_1753425917726862&rfr_iscdi=true |